New hope for advanced breast cancer: experimental drug targets resistant tumors
NCT ID NCT07214662
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 3 times
Summary
This early-stage trial tests a new drug, GDC-0587, alone or with another drug (giredestrant), in people with advanced ER-positive, HER2-negative breast cancer whose cancer worsened after prior CDK4/6 inhibitor therapy. The study aims to find safe doses and check for side effects. About 136 participants will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cheng Kung University Hospital
RECRUITINGTainan, 70403, Taiwan
-
National Taiwan University Hospital
RECRUITINGTaipei, Taipei City, 10002, Taiwan
-
START - Midwest - EDOS
RECRUITINGGrand Rapids, Michigan, 49546-7062, United States
-
START - San Antonio - EDOS
RECRUITINGSan Antonio, Texas, 78229-3307, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?